Article Information
History
- August 29, 2020.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Author Information
- N. Ahmad Aziz1 (ahmad.aziz{at}dzne.de),
- Victor M Corman2 (victor.corman{at}charite.de),
- Antje K.C. Echterhoff3 (antje.echterhoff{at}dzne.de),
- Anja Richter2 (anja.richter{at}charite.de),
- Antonio Schmandke3 (antonio.schmandke{at}dzne.de),
- Marie Luisa Schmidt2 (marie.schmidt{at}charite.de),
- Thomas H. Schmidt3 (thomas.schmidt{at}dzne.de),
- Folgerdiena M De Vries3 (dianna.devries{at}dzne.de),
- Christian Drosten2 (christian.drosten{at}charite.de) and
- Monique M.B. Breteler4,5 (monique.breteler{at}dzne.de)
- 1 Population Health Sciences, German Center for Neurodegenerative Diseases (DZNE) & Department of Neurology, Faculty of Medicine, University of Bonn;
- 2 National Consultant Laboratory for Coronaviruses, Institute of Virology, Charite - Universitätsmedizin Berlin;
- 3 Population Health Sciences, German Center for Neurodegenerative Diseases (DZNE);
- 4 Population Health Sciences, German Center for Neurodegenerative diseases (DZNE) & Institute for Medical Biometry, Informatics and Epidemiology (IMBIE), Faculty of Medicine, University of Bonn
- ↵* Corresponding author; email: monique.breteler{at}dzne.de
Posted August 29, 2020.
Seroprevalence and correlates of SARS-CoV-2 neutralizing antibodies: Results from a population-based study in Bonn, Germany
